Phenotypic assessment of antiviral activity for spiro-annulated oxepanes and azepenes.

Autor: Osolodkin DI; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia.; Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia., Kozlovskaya LI; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Iusupov IR; Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia., Kurkin AV; Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia., Shustova EY; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Orlov AA; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia.; Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia., Khvatov EV; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Mutnykh ES; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Kurashova SS; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Vetrova AN; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Yatsenko DO; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Goryashchenko AS; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Ivanov VN; Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia., Lukyanenko ER; Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia., Karpova EV; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Stepanova DA; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Volok VP; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Sotskova SE; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Dzagurova TK; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia., Karganova GG; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Lukashev AN; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Ishmukhametov AA; FSASI 'Chumakov FSC R&D IBP RAS' (Institute of Poliomyelitis), Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia.
Jazyk: angličtina
Zdroj: Chemical biology & drug design [Chem Biol Drug Des] 2024 May; Vol. 103 (5), pp. e14553.
DOI: 10.1111/cbdd.14553
Abstrakt: Evolutionary potential of viruses can result in outbreaks of well-known viruses and emergence of novel ones. Pharmacological methods of intervening the reproduction of various less popular, but not less important viruses are not available, as well as the spectrum of antiviral activity for most known compounds. In the framework of chemical biology paradigm, characterization of antiviral activity spectrum of new compounds allows to extend the antiviral chemical space and provides new important structure-activity relationships for data-driven drug discovery. Here we present a primary assessment of antiviral activity of spiro-annulated derivatives of seven-membered heterocycles, oxepane and azepane, in phenotypic assays against viruses with different genomes, virion structures, and genome realization schemes: orthoflavivirus (tick-borne encephalitis virus, TBEV), enteroviruses (poliovirus, enterovirus A71, echovirus 30), adenovirus (human adenovirus C5), hantavirus (Puumala virus). Hit compounds inhibited reproduction of adenovirus C5, the only DNA virus in the studied set, in the yield reduction assay, and did not inhibit reproduction of RNA viruses.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: